Matches in SemOpenAlex for { <https://semopenalex.org/work/W2417102424> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2417102424 endingPage "7" @default.
- W2417102424 startingPage "63" @default.
- W2417102424 abstract "Due to the limited efficacy of alpha-interferon for chronic hepatitis C amantadine has been proposed as a possible alternative method of treatment. However, few studies about efficacy of amantadine in chronic hepatitis C are available with controversial results. Stimulated by recent data in the literature, we studied the effect of 100 mg of amantadine HCL (alone) PO bid, for a four month period on alanine aminotransferase serum levels and viral load in a cohort of 18 patients (14 males and 4 females) with chronic hepatitis C, non-responders to alpha-interferon. Inclusion criteria were: detectable serum HCV-RNA, alanine aminotransferase above the upper limit of normal, chronic inflammation on liver biopsy, no other associated chronic liver disease and written informed consent. Available biopsies showed initially four cases of cirrhosis, six of chronic persistent hepatitis and eight of chronic active hepatitis. The most prevalent HCV genotypes were 3a (n = 9, 52.94%) and 1b (n = 6, 32.29%). Viral load (Amplicor HCV Monitor, Roche, USA) and alanine aminotransferase levels were obtained at baseline and after four months of treatment. All patients enrolled into the study but one completed the treatment. One patient discontinued amantadine due to severe depression. No significant reduction was observed between baseline and final values of alanine aminotransferase (139.118 +/- 79.789 vs. 99.588 +/- 62.583 U/L, P = 0.059) and viral load (7.154 +/- 1.596 vs. 6.574 +/- 1.584 log copies/mL, P = 0.147). Amantadine alone was not effective neither eradicating viremia nor normalizing alanine aminotransferase levels in chronic hepatitis C non-responders to alpha-interferon patients. It is suggested that only a study with amantadine alone in-patients without previous treatments could determine its efficacy in comparison with alpha-interferon." @default.
- W2417102424 created "2016-06-24" @default.
- W2417102424 creator A5013504895 @default.
- W2417102424 creator A5052083257 @default.
- W2417102424 creator A5083397090 @default.
- W2417102424 date "1999-10-08" @default.
- W2417102424 modified "2023-09-26" @default.
- W2417102424 title "[Amantadine-HCL in the treatment of chronic hepatitis C in non-responders to alpha-interferon. Effect on ALT serum levels and viral load]." @default.
- W2417102424 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10511883" @default.
- W2417102424 hasPublicationYear "1999" @default.
- W2417102424 type Work @default.
- W2417102424 sameAs 2417102424 @default.
- W2417102424 citedByCount "6" @default.
- W2417102424 crossrefType "journal-article" @default.
- W2417102424 hasAuthorship W2417102424A5013504895 @default.
- W2417102424 hasAuthorship W2417102424A5052083257 @default.
- W2417102424 hasAuthorship W2417102424A5083397090 @default.
- W2417102424 hasConcept C126322002 @default.
- W2417102424 hasConcept C142462285 @default.
- W2417102424 hasConcept C203014093 @default.
- W2417102424 hasConcept C2522874641 @default.
- W2417102424 hasConcept C2775934546 @default.
- W2417102424 hasConcept C2776178377 @default.
- W2417102424 hasConcept C2776408679 @default.
- W2417102424 hasConcept C2776455275 @default.
- W2417102424 hasConcept C2776461080 @default.
- W2417102424 hasConcept C2777072776 @default.
- W2417102424 hasConcept C2777214474 @default.
- W2417102424 hasConcept C2777374534 @default.
- W2417102424 hasConcept C2777766500 @default.
- W2417102424 hasConcept C2778606649 @default.
- W2417102424 hasConcept C2780040827 @default.
- W2417102424 hasConcept C2909179924 @default.
- W2417102424 hasConcept C2992872382 @default.
- W2417102424 hasConcept C71924100 @default.
- W2417102424 hasConcept C90924648 @default.
- W2417102424 hasConcept C98274493 @default.
- W2417102424 hasConceptScore W2417102424C126322002 @default.
- W2417102424 hasConceptScore W2417102424C142462285 @default.
- W2417102424 hasConceptScore W2417102424C203014093 @default.
- W2417102424 hasConceptScore W2417102424C2522874641 @default.
- W2417102424 hasConceptScore W2417102424C2775934546 @default.
- W2417102424 hasConceptScore W2417102424C2776178377 @default.
- W2417102424 hasConceptScore W2417102424C2776408679 @default.
- W2417102424 hasConceptScore W2417102424C2776455275 @default.
- W2417102424 hasConceptScore W2417102424C2776461080 @default.
- W2417102424 hasConceptScore W2417102424C2777072776 @default.
- W2417102424 hasConceptScore W2417102424C2777214474 @default.
- W2417102424 hasConceptScore W2417102424C2777374534 @default.
- W2417102424 hasConceptScore W2417102424C2777766500 @default.
- W2417102424 hasConceptScore W2417102424C2778606649 @default.
- W2417102424 hasConceptScore W2417102424C2780040827 @default.
- W2417102424 hasConceptScore W2417102424C2909179924 @default.
- W2417102424 hasConceptScore W2417102424C2992872382 @default.
- W2417102424 hasConceptScore W2417102424C71924100 @default.
- W2417102424 hasConceptScore W2417102424C90924648 @default.
- W2417102424 hasConceptScore W2417102424C98274493 @default.
- W2417102424 hasIssue "2" @default.
- W2417102424 hasLocation W24171024241 @default.
- W2417102424 hasOpenAccess W2417102424 @default.
- W2417102424 hasPrimaryLocation W24171024241 @default.
- W2417102424 hasRelatedWork W118298973 @default.
- W2417102424 hasRelatedWork W1976724544 @default.
- W2417102424 hasRelatedWork W2007217713 @default.
- W2417102424 hasRelatedWork W2027650820 @default.
- W2417102424 hasRelatedWork W2034664495 @default.
- W2417102424 hasRelatedWork W2082200384 @default.
- W2417102424 hasRelatedWork W2169842128 @default.
- W2417102424 hasRelatedWork W2417102424 @default.
- W2417102424 hasRelatedWork W651249740 @default.
- W2417102424 hasRelatedWork W2467456162 @default.
- W2417102424 hasVolume "36" @default.
- W2417102424 isParatext "false" @default.
- W2417102424 isRetracted "false" @default.
- W2417102424 magId "2417102424" @default.
- W2417102424 workType "article" @default.